221559-22-4

Basic information

• Product Name: 1,2-Benzisoxazol-5-amine,6-fluoro-3-methyl-(9CI)
• Synonyms: 1,2-Benzisoxazol-5-amine,6-fluoro-3-methyl-(9CI);6-FLUORO-3-METHYLBENZO[D]ISOXAZOL-5-AMINE;6-fluoro-3-methyl-1,2-Benzisoxazol-5-amine
• CAS NO: 221559-22-4
• Molecular Formula: C8H7FN2O
• Molecular Weight: 166.154
• Product Categories: OXAZOLE
• Mol File: 221559-22-4.mol

Chemical Properties

• Boiling Point: 308.888 °C at 760 mmHg
• Flash Point: 140.611 °C
• Appearance: /
• Density: 1.358 g/cm³
• Vapor Pressure: 0.000662mmHg at 25°C
• Refractive Index: 1.63
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,2-Benzisoxazol-5-amine,6-fluoro-3-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Benzisoxazol-5-amine,6-fluoro-3-methyl-(9CI)(221559-22-4)
• EPA Substance Registry System: 1,2-Benzisoxazol-5-amine,6-fluoro-3-methyl-(9CI)(221559-22-4)

Safety Data

• Hazardous Substances Data: 221559-22-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,2-Benzisoxazol-5-amine,6-fluoro-3-methyl-(9CI) is used as a pharmaceutical agent for its potential therapeutic applications in the treatment of cancer. Its ability to inhibit the enzyme PARP makes it a promising candidate for targeting cancer cells and enhancing the efficacy of other cancer treatments.
Used in Medicinal Chemistry Research:
Due to its unique structure and chemical properties, 1,2-Benzisoxazol-5-amine,6-fluoro-3-methyl-(9CI) is used as a target for further research and development in the field of medicinal chemistry. Its potential as a PARP inhibitor and its involvement in various cellular processes make it an interesting compound for exploring new drug candidates and therapeutic strategies.
Used in DNA Repair and Programmed Cell Death Studies:
1,2-Benzisoxazol-5-amine,6-fluoro-3-methyl-(9CI) is used as a research tool in studies related to DNA repair mechanisms and programmed cell death. Its activity as a PARP inhibitor allows researchers to investigate the role of this enzyme in these processes and develop a better understanding of its implications in various diseases, including cancer.

InChI:InChI=1/C8H7FN2O/c1-4-5-2-7(10)6(9)3-8(5)12-11-4/h2-3H,10H2,1H3

Upstream product

• 221559-21-3 6-fluoro-3-methyl-5-nitro-1,2-benzisoxazole 

Downstream Products

• 1243313-45-2 5-amino-6-fluoro-3-methylbenzo[d]isoxazole hydrochloride 

Relevant articles and documents

7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-YL)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5amine

The compound having the structural formula I or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.

2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1-isoxazolyl, R1-oxadiazolyl, R1-dihydrofuranyl, R1-pyrazolyl, R1-imidazolyl, R1-pyrazinyl or R1-pyrimidinyl; R1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.